Optimizing the design of population-based patient-derived tumor xenograft studies to better predict clinical response

The high attrition rate of preclinical agents entering oncology clinical trials has been associated with poor understanding of the heterogeneous patient response, arising from limitations in the preclinical pipeline with cancer models. Patient-derived tumor xenograft (PDX) models have been shown to...

Descripción completa

Detalles Bibliográficos
Autores principales: Floc'h, Nicolas, Guerriero, Maria Luisa, Ramos-Montoya, Antonio, Davies, Barry R., Cairns, Jonathan, Karp, Natasha A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Company of Biologists Ltd 2018
Materias:
Resource Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262806/
https://www.ncbi.nlm.nih.gov/pubmed/30254068
http://dx.doi.org/10.1242/dmm.036160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262806/
https://www.ncbi.nlm.nih.gov/pubmed/30254068
http://dx.doi.org/10.1242/dmm.036160

Ejemplares similares